| Literature DB >> 31294001 |
Elizabeth Whittaker1,2, Elisa López-Varela3, Claire Broderick1, James A Seddon1,2,3.
Abstract
Millions of children are exposed to tuberculosis (TB) each year, many of which become infected with Mycobacterium tuberculosis. Most children can immunologically contain or eradicate the organism without pathology developing. However, in a minority, the organism overcomes the immunological constraints, proliferates and causes TB disease. Each year a million children develop TB disease, with a quarter dying. While it is known that young children and those with immunodeficiencies are at increased risk of progression from TB infection to TB disease, our understanding of risk factors for this transition is limited. The most immunologically disruptive process that can happen during childhood is infection with another pathogen and yet the impact of co-infections on TB risk is poorly investigated. Many diseases have overlapping geographical distributions to TB and affect similar patient populations. It is therefore likely that infection with viruses, bacteria, fungi and protozoa may impact on the risk of developing TB disease following exposure and infection, although disentangling correlation and causation is challenging. As vaccinations also disrupt immunological pathways, these may also impact on TB risk. In this article we describe the pediatric immune response to M. tuberculosis and then review the existing evidence of the impact of co-infection with other pathogens, as well as vaccination, on the host response to M. tuberculosis. We focus on the impact of other organisms on the risk of TB disease in children, in particularly evaluating if co-infections drive host immune responses in an age-dependent way. We finally propose priorities for future research in this field. An improved understanding of the impact of co-infections on TB could assist in TB control strategies, vaccine development (for TB vaccines or vaccines for other organisms), TB treatment approaches and TB diagnostics.Entities:
Keywords: children; co-infection; immunology; mycobacteria; pediatric; risk; tuberculosis
Year: 2019 PMID: 31294001 PMCID: PMC6603259 DOI: 10.3389/fped.2019.00233
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.418
Figure 1Times in disease spectrum and progression when co-infections may have an influence.
Figure 2Incidence of childhood tuberculosis is greatest in infants and adolescents; a number of factors increase the risk in these age groups, including co-infections, hormones, behavior, and epidemiological risk factors.
Figure 3Global incidence of tuberculosis (A), HIV (B), Helminths (C), and malaria (D)—demonstrating geographical overlap between these 4 infections, supporting a role for interplay between them. Panel (A) was reproduced from © World Health Organization (2). Panel (B) was reproduced from © World Bank -WDI (6). Panel (C) was reproduced from © World Health Organization 2015 (7). Panel (D) was reproduced from © World Bank -WDI (8). Data from WHO Malaria Report (9).
Figure 4Although a “protective immune response” to tuberculosis remains elusive, a Th1 predominant response is associated with protection, while a Th2 and regulatory T cell predominance has been described in association with severe disease and dissemination. We propose that the balance of these immune responses is influenced by co-infections including helminths, CMV, hepatitis viral infections, malaria, measles, etc. IFN, interferon; IgG, Immunoglobulin G; TNF, tumor necrosis factor; T reg, regulatory T cell; IL, interleukin; TGF, tumor growth factor; HIV, human immunodeficiency virus; CMV, cytomegalovirus.
A summary of (1) the predominant immune response associated with a variety of pathogens in children and (2) the known impact of that pathogen on tuberculosis pathogenesis.
| TB | Th1, IFNγ, IFNα, TNFα, IL12, IL23, IL17, IL2 | Severe disease- increased regulatory T cells, suppressed Th1, excessive neutrophils |
| HIV | Decreased Th1, Low IFNγ, increased apoptosis due to IL10 and XS TNFα. Specific depletion of CD27 activated mycobacterial specific CD4+ T cells | Increased pathogenesis, increased risk of infection, disease, and severe disseminated disease |
| CMV | Adults—clonal expansion CMV specific CD4+ and CD8+ T cells Children—suppressed IFNγ producing CD4+ T cells compared to adults | CMV specific IFNγ producing T cells and T cell activation associated with increased risk of TB disease progression. |
| EBV | CD8+ T cell response predominates, strong type I IFN response | Unknown |
| HHV6/HHV7/HSV | Increased NK cells, CD4, and CD8 clonal expansion | Unknown in humans |
| Hepatitis B and C | Hep B—CD8+ cytotoxic T cells, Type I interferon, NK cells. Chronic infection—increased regulatory T cells, raised IL10, suppressed IFNα, IFNγ | Unexplored, but chronic infection with either Hepatitis B or C is associated with higher regulatory T cells and IL10, lower IFNγ, IFNα which may increase susceptibility to TB in children |
| Microbiome and gut-lung axis | Modulates innate immune responses through TLR stimulation— | Hypothesized to be protective through persistent Th1 stimulation Unknown if different bacteria cause differential stimulation of Th1 leading to changes in susceptibility |
| Adenovirus | Primary Adenovirus infection suppresses IFNγ, while secondary reactivation leads to increased IFNγ, as well as HLADR+ and Ki67+ T cells | Adenovirus primary infection may result in immunosuppression, while secondary infection may result in T cell activation (as measured by HLA-DR), both associated with increased risk of TB disease progression |
| Respiratory viruses | Influenza—induces type I IFN signaling pathway | Influenza—seasonal association with TB disease possibly due to local lung damage |
| Measles | Increased IL6, IL1b, TNFα, IL8, decreased IL12, IFNα. Th2 responses and increased regulatory T cells predominate for several weeks the acute infection | Measles infection associated with transient immunosuppression for weeks/months—recorded increased incidence TB disease in children, in particular TB meningitis |
| Fungi | Similar immune responses—Th1, poor TLR stimulation, granuloma formation | Co-infection, or concurrent infection likely due to lung damage rather than immune impact on susceptibility |
| Respiratory bacteria | TLR and NLR stimulation by bacteria stimulates phagocytes and a subsequent innate immune response including natural killer cells, pro-inflammatory cytokines, and adaptive immunity via T and B cells | TB often complicated by bacterial co-infection, or TB follows bacterial damaged lungs. Co-infection associated with increased mortality |
| Other non-TB bacteria | Intracellular bacterial infections elicit similar cell mediated response (CD4+ CD8+ and T cell activation) | Similar immune responses may represent protection. Co-infection not commonly reported |
| NTMs | Th1 immunity including CD4+ T cells responses and neutrophils all essential for protection against NTM infections | TB disease and lung damage likely to predispose to NTM, rather than the other way around. Concurrent infection seen |
| Helminths | IgE, IgG4, Th2 cytokines (IL4, IL9, IL13), Regulatory T cells and cytokines (TGFβ, IL10) | Shift away from Th1 likely to contribute to immune susceptibility and progression to disease. Mixed evidence to date |
| Malaria | Pro-inflammatory cytokines (IL1β, IL6, IL12, TNFα, IFNγ) stimulated by infection. Severe disease associated with decreased levels of CD4+ cells and associated immunosuppression | Severe malaria disease associated with Th2, IL10, and low CD4/immunosuppression which may increase susceptibility to TB disease |
| Other protozoa | Suppressed Th1 responses (low IL12) | Likely to impact TB immune responses, limited evidence |
| Routine vaccinations | Increased total IgG levels | Protective against TB infection |
IFN, interferon; IgG, Immunoglobulin G; TNF, tumor necrosis factor; IL, interleukin; TGF, tumor growth factor; HIV, human immunodeficiency virus; CMV, cytomegalovirus; EBV, Epstein Barr Virus; HLA-DR, human leukocyte antigen-DR; HHV, human herpes virus; NK, natural killer; TLR, Toll like receptors; RSV, respiratory syncytiovirus; NLR, nod- like receptor.
Type of vaccines and how they may influence susceptibility and protection to tuberculosis in children.
| Live attenuated vaccine | Measles, mumps Rubella (MMR) Rotavirus Varicella Yellow Fever BCG | Induce cytotoxic T cells CD4 and CD8 Heterologous immune responses, in particular BCG | Cytotoxic T cells more IFN—greater anti-TB immune responses Possible mechanism for protection against disseminated BCG |
| Inactivated vaccine | Hepatitis Influenza A Inactivated polio | Th2 stimulation | Th2 predominant—less effective anti-TB immune response |
| Toxoid vaccines | Diphtheria Tetanus | Th2 stimulation | Th2 predominant—less effective anti-TB immune response |
| Subunit/conjugate | Haemophilus influenza b (Hib) Pneumococcus Meningococcal B & C Hepatitis B Human papillomavirus | Polysaccheride vaccines—T cell independent response, no Th2 | Th2 predominant—less effective anti-TB immune response |
Not complete list of immune responses, describing commonest, or predominant immune response.
Potential study designs to answer the priority research questions in the field of tuberculosis co-infections.
| Basic science research | Does co-infection influence mycobacterial immune responses? | Evaluate interaction between host and Impact on novel diagnostics based on host transcriptomics. Presumed altered results if different co-infections—need to include diagnostic tests for co-infection as part of these studies |
| Surveys of disease prevalence | Describe the epidemiology of TB-pathogen co-infection in a variety of geographical areas Describe the impact of other environmental factors/interventions on TB exposure outcomes | Quantify how common co-infections are in children of different ages, in different geographical areas and evaluate in: (a) all children; (b) children exposed to TB; (c) children with TB infection; (d) children with TB disease. These studies would also ideally collect samples for serological analyses, transcriptomics, presences of pathogen particles in blood (antigen/PCR) and culture samples from blood or other sites Determine the effect of malnutrition (worsening of microbiome and associated with helminth), HIV, and other comorbidities on the immune response to TB |
| Longitudinal cohorts | Describe the natural history of TB exposure in children following a variety of different exposures/interventions | Mother -infant and birth cohort studies—exploring influence of co-infections on mycobacterial responses or outcomes following household TB exposure TB natural history studies—observational and interventional cohorts taking part in MDR-TB chemoprophylaxis studies Infants born to mothers taking part in maternal vaccination studies—these infants will be having samples taken to explore the impact of maternal immunization on their vaccine responses, need to gather data on co-infections, TB exposure and outcome as part of these studies |
| Vaccine cohorts | Do co-infections affect efficacy or immunogenicity of novel vaccine candidates | Explore influence of co-infections on pediatric and adult cohorts taking part in novel vaccine studies. These studies would also ideally collect samples for serological analyses, transcriptomics, presences of pathogen particles in blood (antigen/PCR), and culture samples from blood or other sites and analyse the impact of various pathogens isolated |
| Direct studies of co-infection | Do interventions to change co-infections alter outcome following TB exposure | Evaluation of host directed therapies to mitigate effects of co-infections. Evaluation of novel vaccine candidates, or booster doses of BCG to mitigate effects of co-infections |
| Programmatic changes | Can optimisation of current programmes improve TB outcomes | PMTCT—great success, what can we do to improve it, and improved access to ARV in those who are infected, in particular young women who may become pregnant Impact of interventions which may influence early childhood illnesses impact on the risk and outcomes of TB (i.e., promotion of maternal health and antenatal care, which may in turn influence microbiome, birth weight, maternal antibody transfer, and protection) |